C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19 Clinicians to report novel uses of existing drugs through FDA-NCATS CURE ID Mobile App. TUCSON, Ariz., June 23, 2020 — As millio
June 19, 2020 Method of Blood Pressure Measurement in Neonates and Infants: A Systematic Review and Analysis
June 20, 2020 C-Path’s Transplant Therapeutics Consortium Receives Acceptance of Letter of Intent for iBox Scoring System (Composite Biomarker Panel) as a Reasonably Likely Surrogate Endpoint Biomarker aims to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplan
June 24, 2020 Watch now: Shortening the Timeline for Developing New Treatments – How the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) Can Help Webinar Join C-Path, the National Organization for Rare Disorders and the FDA for a free 1-hour webinar on the Rare Disease Cures Accelera
June 14, 2020 Standardized Data Structures in Rare Diseases: CDISC User Guides for Duchenne Muscular Dystrophy and Huntington’s Disease
June 12, 2020-June 18, 2020 The Rare Disease Clinical Outcome Assessment Consortium: Aiming to Fulfill Unmet Drug Development Endpoint Measurement Needs Presented at the DIA Virtual Global Annual Meeting, held June 12 – 18, 2020.
From the Regulatory Affairs Professional Society (RAPS): FDA’s CURE ID app gets a COVID-19 refresh An online case reporting platform has been optimized for COVID-19 and will be the springboard for a new public-private drug
September 6, 2020 Webinar: FDA Drug Topics: CURE ID: Capturing Clinician’s Experiences Repurposing Drugs to Inform Future Studies in the Era of COVID-19 This new webinar from the Center for Drug Evaluation (CDER), Division of Drug Information (DDI) is now available at:
May 6, 2020 Webinar: What you want and need to know about the Rare Disease Cures Accelerator – Data and Analytics Platform (May 6, 2020)
